Page 23 - Clinical Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Daiichi Sankyo Company, Limited: DESTINY-CRC02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer Interstitial Lung Disease Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation...

Published: Mar 16, 2021 NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23 rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics’ development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include: Update on ACTION-Galactosemia Clinical Dev...

DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered

Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer ii 80% (n=64) CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response i Includes patients with =1 postbaseline scan or who discontinued treatment. ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5). iii DCR is CR+PR+SD iv Preliminary PFS limited by earlier censoring b...

Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society January 27, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU ® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister’s Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with the obje...